Pharmacogenomics
Abstract
We all differ in our response to drug treatment—occasionally with dramatic effects The era of “one drug fits all patients” is about to give way to individualised therapy matching the patient's unique genetic make up with an optimally effective drug.1 Pharmacogenetics and pharmacogenomics are the emerging disciplines that are leading the way towards individualised medicine. 2 3 Initially, researchers focused their attention on pharmacogenetics—variations in single candidate genes responsible for variable drug response. Subsequently, studies involving the entire human genome broadened the scope of investigation, giving rise to pharmacogenomics as one of the “hottest” fields in biotechnology today. #### Summary points Response to drug treatment can vary greatly between patients; genetic factors have a major role in treatment outcome Pharmacogenetics and pharmacogenomics are emerging disciplines that focus on genetic determinants of drug response at the levels of single genes or the entire human genome respectively Technologies involving gene chip arrays can determine thousands of variations in DNA sequences for individual patients; most variants are single nucleotide polymorphisms Pharmacogenomics aims at establishing a signature of DNA sequence variants that are characteristic of individual patients to assess disease susceptibility and select the optimal drug treatment This approach has the potential to revolutionise prevention and treatment of diseases Unexpected drug reactions have been noted for some time, but the systematic study of hereditary origins began only in the 1950s. A few patients developed prolonged respiratory muscular paralysis after being given succinylcholine (suxamethonium), a short acting muscle relaxant widely used in surgery and electroshock treatment. In the 1970s, a trial with the antihypertensive agent debrisoquine resulted in a precipitous drop of blood pressure and collapse in nearly 10% of volunteers. Furthermore, isoniazid therapy for tuberculosis caused peripheral neuropathies in patients who were sensitive to the neurotoxic effects of the drug. Ground breaking genetic and biochemical studies …Keywords
This publication has 14 references indexed in Scilit:
- Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancerClinical Therapeutics, 1999
- The Transcriptional Program in the Response of Human Fibroblasts to SerumScience, 1999
- Microchip Arrays Put DNA on the SpotScience, 1998
- Genetic Variation as a Guide to Drug DevelopmentScience, 1998
- The Environmental Genome Project: functional analysis of polymorphisms.Environmental Health Perspectives, 1998
- Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.1998
- Genomics and Drugs: Finding the Optimal Drug for the Right PatientPharmaceutical Research, 1998
- Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles of CYP2D6 in a European PopulationDNA and Cell Biology, 1991
- Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylationClinical Pharmacology & Therapeutics, 1985
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960